GlobeNewswire

Call for Speakers Now Open for Percona Live Open Source Database Conference Europe 2018

Dela

Annual Conference Moves to Frankfurt; Accepting Speaker Proposals Through August 10, 2018

RALEIGH, N.C., July 10, 2018 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MariaDB and MongoDB®, PostgreSQL and other open source database solutions and services, today announced the Call for Speakers for Percona Live Open Source Database Conference Europe 2018 is open and accepting proposals through August 10, 2018. The Percona Live Open Source Database Conference Europe 2018 will take place November 5-7, 2018, at the Radisson Blu Frankfurt hotel in Frankfurt, Germany. Sponsorship opportunities are now available.

The Percona Live Open Source Database Conference Europe 2018 is the premier open source database event. The theme for the upcoming conference is "Connect. Accelerate. Innovate." Percona Live conferences provide the open source database community with an opportunity to discover and discuss the latest open source trends, technologies and innovations. The conference includes the best and brightest innovators and influencers in the open source database industry.

The 2018 conference will introduce a new "business" track, which will take place on Monday, November 5. The new track will be targeted to business leaders who are exploring the use of open source and are interested in learning more about its benefits as well as common business pains and how these have been addressed through use cases and case studies.

The conference committee is looking for proposals that cover the many aspects of using, deploying and managing open source databases, including:

  • Security - All of us have experienced security challenges. Whether they are initiated by legislature (GDPR), bugs (Meltdown/Spectre), experience (external attacks) or due diligence (planning for the worst), when do you have 'enough' security? Are you finding that security requirements are preventing your from being agile?
  • Serverless, Cloud or On Premise - The technology landscape is no longer a simple one and mixing infrastructures has almost become the norm. Are you designing data architectures for the new landscape, and eager to share your experience? Have microservices become an important part of your plans?
  • MySQL - Do you have an opinion on what is new and exciting in MySQL? With the release of MySQL 8.0, are you using the latest features? How and why? Are they helping you solve any business issues, or making deployment of applications and websites easier, faster or more efficient? Did the new release get you to change to MySQL? What do you see as the biggest impact of the MySQL 8.0 release? Do you use MySQL in conjunction with other databases in your environment?
  • MongoDB - How has the 3.6 release improved your experience in application development or time-to-market? How are the new features making your database environment better? What is it about MongoDB 4.0 that excites you? What are your experiences with Atlas? Have you moved to it, and has it lived up to its promises? Do you use MongoDB in conjunction with other databases in your environment?
  • PostgreSQL - Why do you use PostgreSQL as opposed to other SQL options? Have you done a comparison or benchmark of PostgreSQL vs. other types of databases related to your tasks? Why and what were the results? How does PostgreSQL help you with application performance or deployment? How do you use PostgreSQL in conjunction with other databases in your environment?
  • SQL, NewSQL, NoSQL - It's become a perennial question without an easy answer. How do databases compare, how do you choose the right technology for the job, how do you trade off between features and their benefits in comparing databases? If you have ever tried a hybrid database approach in a single application, how did that work out? How nicely does MongoDB play with MySQL in the real world? Do you have anything to say about using SQL with NoSQL databases?
  • High Availability - What choices are you making to ensure high availability? How do you find the balance between redundancy and cost? Are you using hot backups, and if so, what happened when you needed to rollback on them? 
  • Scalability - When did you recognize you needed to address data scale? Did your data growth take you by surprise or were you always in control? Did it take a degradation in performance to get your management to sit up and take notice? How do you plan for scale if you can't predict demand?
  • What the Future Holds - What do you see as the "next big thing"? What new and exciting features are going to be released? What's in your next release? What new technologies will affect the database landscape? AI? Machine learning? Blockchain databases? Let us know about innovations you see on the way.

Breakout sessions are 50 minutes in length, including a Q&A. Tutorial sessions are three or six hours in length, focused on an immediate and practical application of in-depth knowledge, and targeted at a level between a training class and a conference breakout session. Tutorial speakers should assume that attendees will have laptops to work through detailed and potentially hands-on presentations. Lightning Talks are five-minute presentations focusing on one key point that interests the open source community: technical, lighthearted or entertaining talks on new ideas, a successful project, a cautionary story, a quick tip or demonstration.

Selected speakers will receive a complimentary full conference pass.

Sponsorships
Sponsorship opportunities for Percona Live Open Source Database Conference Europe 2018 are available and offer the opportunity to interact with hundreds of DBAs, sysadmins, developers, CTOs, CEOs, business managers, technology evangelists, solution vendors, and entrepreneurs who typically attend the event. Contact live@percona.com for sponsorship details.

Percona Live Conferences

What:               Percona Live Open Source Database Conference Europe 2018 
Where:            Radisson Blu Frankfurt, Franklinstraße 65, Frankfurt, Germany
When:              November 5-7, 2018
Call for Papers Deadline:  August 10, 2018

Company Information

Press Contact
Brigit Valencia
For Percona
(360) 597-4516
bdbvalencia@gmail.com

About Percona

With more than 3,000 customers worldwide, Percona is the only company that delivers enterprise-class solutions for both MySQL® MariaDB®, MongoDB® and PostgreSQL across traditional and cloud-based platforms. The company provides SoftwareSupport,  Consulting, and Managed Services to large, well-known global brands such as Cisco Systems, Time Warner Cable, Alcatel-Lucent, Rent the Runway and the BBC, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. Well established as thought leaders, Percona experts author content for the Percona Database Performance Blog and the Percona Live Open Source Database Conferences draw attendees and expert technical speakers from around the world. For more information, visit www.percona.com.

Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Percona via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum